100 related articles for article (PubMed ID: 27919971)
1. Usefulness of 18F-α-Methyltyrosine PET for Therapeutic Monitoring of Patients with Advanced Lung Cancer.
Kaira K; Higuchi T; Sunaga N; Arisaka Y; Hisada T; Tominaga H; Oriuchi N; Asao T; Tsushima Y; Yamada M
Anticancer Res; 2016 Dec; 36(12):6481-6490. PubMed ID: 27919971
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of metabolic tumor volume of pretreatment
Kumasaka S; Nakajima T; Arisaka Y; Tokue A; Achmad A; Fukushima Y; Shimizu K; Kaira K; Higuchi T; Tsushima Y
BMC Med Imaging; 2018 Nov; 18(1):46. PubMed ID: 30477476
[TBL] [Abstract][Full Text] [Related]
3. Relationship Between Tumor Immune Markers and Fluorine-18-α-Methyltyrosine ([
Shimizu K; Kaira K; Higuchi T; Hisada T; Yokobori T; Oyama T; Asao T; Tsushima Y; Shirabe K
Mol Imaging Biol; 2020 Aug; 22(4):1078-1086. PubMed ID: 31792836
[TBL] [Abstract][Full Text] [Related]
4. Effects of intratumoral inflammatory process on 18F-FDG uptake: pathologic and comparative study with 18F-fluoro-α-methyltyrosine PET/CT in oral squamous cell carcinoma.
Kim M; Achmad A; Higuchi T; Arisaka Y; Yokoo H; Yokoo S; Tsushima Y
J Nucl Med; 2015 Jan; 56(1):16-21. PubMed ID: 25476535
[TBL] [Abstract][Full Text] [Related]
5. Biological evaluation of 3-[(18)F]fluoro-α-methyl-D-tyrosine (D-[(18)F]FAMT) as a novel amino acid tracer for positron emission tomography.
Ohshima Y; Hanaoka H; Tominaga H; Kanai Y; Kaira K; Yamaguchi A; Nagamori S; Oriuchi N; Tsushima Y; Endo K; Ishioka NS
Ann Nucl Med; 2013 May; 27(4):314-24. PubMed ID: 23337966
[TBL] [Abstract][Full Text] [Related]
6. ¹⁸F-FAMT in patients with multiple myeloma: clinical utility compared to ¹⁸F-FDG.
Isoda A; Higuchi T; Nakano S; Arisaka Y; Kaira K; Kamio T; Mawatari M; Matsumoto M; Sawamura M; Tsushima Y
Ann Nucl Med; 2012 Dec; 26(10):811-6. PubMed ID: 22903817
[TBL] [Abstract][Full Text] [Related]
7. Use of pre-treatment 18F-FAMT PET to predict patient survival in squamous cell carcinoma of the esophagus treated by curative surgery.
Sohda M; Sakai M; Honjyo H; Hara K; Ozawa D; Suzuki S; Tanaka N; Yokobori T; Miyazaki T; Fukuchi M; Higuchi T; Tsushima Y; Kuwano H
Anticancer Res; 2014 Jul; 34(7):3623-8. PubMed ID: 24982378
[TBL] [Abstract][Full Text] [Related]
8. Transport of 3-fluoro-L-α-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET.
Wiriyasermkul P; Nagamori S; Tominaga H; Oriuchi N; Kaira K; Nakao H; Kitashoji T; Ohgaki R; Tanaka H; Endou H; Endo K; Sakurai H; Kanai Y
J Nucl Med; 2012 Aug; 53(8):1253-61. PubMed ID: 22743251
[TBL] [Abstract][Full Text] [Related]
9. Complementary roles of tumour specific PET tracer ¹⁸F-FAMT to ¹⁸F-FDG PET/CT for the assessment of bone metastasis.
Morita M; Higuchi T; Achmad A; Tokue A; Arisaka Y; Tsushima Y
Eur J Nucl Med Mol Imaging; 2013 Oct; 40(11):1672-81. PubMed ID: 24006150
[TBL] [Abstract][Full Text] [Related]
10. Biological significance of fluorine-18-α-methyltyrosine (FAMT) uptake on PET in patients with oesophageal cancer.
Suzuki S; Kaira K; Ohshima Y; Ishioka NS; Sohda M; Yokobori T; Miyazaki T; Oriuchi N; Tominaga H; Kanai Y; Tsukamoto N; Asao T; Tsushima Y; Higuchi T; Oyama T; Kuwano H
Br J Cancer; 2014 Apr; 110(8):1985-91. PubMed ID: 24667647
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of ¹⁸F-α-methyl tyrosine PET/CT for the detection of bone marrow invasion in patients with oral squamous cell carcinoma: comparison with ¹⁸F-FDG PET/CT and MRI.
Kim M; Higuchi T; Arisaka Y; Achmad A; Tokue A; Tominaga H; Miyashita G; Miyazaki H; Negishi A; Yokoo S; Tsushima Y
Ann Nucl Med; 2013 Jun; 27(5):423-30. PubMed ID: 23436243
[TBL] [Abstract][Full Text] [Related]
12. 18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer.
Kaira K; Oriuchi N; Shimizu K; Tominaga H; Yanagitani N; Sunaga N; Ishizuka T; Kanai Y; Mori M; Endo K
J Nucl Med; 2009 Nov; 50(11):1770-6. PubMed ID: 19837768
[TBL] [Abstract][Full Text] [Related]
13. Assessment of therapy response in lung cancer with ¹⁸F-α-methyl tyrosine PET.
Kaira K; Oriuchi N; Yanagitani N; Sunaga N; Ishizuka T; Mori M; Endo K
AJR Am J Roentgenol; 2010 Nov; 195(5):1204-11. PubMed ID: 20966329
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic usefulness of ¹⁸F-FAMT PET and L-type amino acid transporter 1 (LAT1) expression in oral squamous cell carcinoma.
Nobusawa A; Kim M; Kaira K; Miyashita G; Negishi A; Oriuchi N; Higuchi T; Tsushima Y; Kanai Y; Yokoo S; Oyama T
Eur J Nucl Med Mol Imaging; 2013 Oct; 40(11):1692-700. PubMed ID: 23801167
[TBL] [Abstract][Full Text] [Related]
15. L-[3-18F]-α-methyltyrosine accumulation as a definitive chemoradiotherapy response predictor in patients with esophageal cancer.
Sohda M; Honjyo H; Hara K; Ozawa D; Suzuki S; Tanaka N; Sano A; Sakai M; Yokobori T; Inose T; Miyazaki T; Ojima H; Higuchi T; Tsushima Y; Kuwano H
Anticancer Res; 2014 Feb; 34(2):909-13. PubMed ID: 24511031
[TBL] [Abstract][Full Text] [Related]
16. ¹⁸F-FAMT uptake correlates with tumor proliferative activity in oral squamous cell carcinoma: comparative study with ¹⁸F-FDG PET and immunohistochemistry.
Miyashita G; Higuchi T; Oriuchi N; Arisaka Y; Hanaoka H; Tominaga H; Morita S; Miyakubo M; Ishikita T; Nakasone Y; Negishi A; Yokoo S; Endo K
Ann Nucl Med; 2010 Oct; 24(8):579-84. PubMed ID: 20652456
[TBL] [Abstract][Full Text] [Related]
17.
Kim M; Higuchi T; Nakajima T; Andriana P; Hirasawa H; Tokue A; Kurihara J; Yokoo S; Tsushima Y
Oral Radiol; 2019 Sep; 35(3):308-314. PubMed ID: 30778900
[TBL] [Abstract][Full Text] [Related]
18. 18F-FAMT PET Is Useful to Distinguish between Specific Uptake and Nonspecific Uptake Compared to 18F-Flourodeoxyglucose Position Emission Tomography in Esophageal Cancer Patients.
Sohda M; Miyazaki T; Honjyo H; Hara K; Ozawa D; Sakai M; Yokobori T; Higuchi T; Tsushima Y; Kuwano H
Dig Surg; 2018; 35(5):383-388. PubMed ID: 29130979
[TBL] [Abstract][Full Text] [Related]
19. Transport of 3-fluoro-L-α-methyl-tyrosine (FAMT) by organic ion transporters explains renal background in [(18)F]FAMT positron emission tomography.
Wei L; Tominaga H; Ohgaki R; Wiriyasermkul P; Hagiwara K; Okuda S; Kaira K; Kato Y; Oriuchi N; Nagamori S; Kanai Y
J Pharmacol Sci; 2016 Feb; 130(2):101-9. PubMed ID: 26887331
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of 18F-FDG uptake on PET in non-small cell lung cancer patients with postoperative recurrence following platinum-based chemotherapy.
Kaira K; Yamamoto N; Kenmotsu H; Murakami H; Ono A; Naito T; Endo M; Takahashi T
Respir Investig; 2014 Mar; 52(2):121-8. PubMed ID: 24636268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
